Antibiotics as biological response modifiers

Journal of Antimicrobial Chemotherapy

Volumn 26, Issue , 1990, Pages 31-36

  Ritts, R E ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFODIZIME; CEFOTAXIME; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; PENTOXIFYLLINE; POLYMYXIN; TUMOR NECROSIS FACTOR;

BACTERIAL INFECTION; CONFERENCE PAPER; HUMAN; IMMUNOMODULATION; INFECTION; INTRACELLULAR KILLING; MONOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPTIC SHOCK; VIRUS INFECTION;

ANTIBIOTICS; BIOLOGICAL RESPONSE MODIFIERS; HUMAN; SUPPORT, NON-U.S. GOV'T;

EID: 0025242294     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/26.suppl_C.31     Document Type: Article

References (8)

1. Morrison, D. C. & Jacobs, D. M., (1976). Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13, 813–8.
2. Rifkind, D. (1967). Prevention by polymyxin B of endotoxin lethality in mice. Journal of Bacteriology 93, 1463–4.
3. Vaara, M. (1983). Polymyxin B nonapeptide complexes with lipopolysaccharide. FEBS Letters 18, 117–21.
4. Vaara, M. & Vaara, T., (1981). Outer membrane permeability barrier disruption by polymyxin susceptible and resistant Salmonella typhimurium. Antimicrobial Agents and Chemotherapy 28, 107–12.
5. Vaara, M. & Vaara, T., (1983). Sensitization of gram-negative bacteria to antibiotics and complement by a nontoxic oligopeptide. Nature 303, 526–528.
6. Warren, H. S., Kania, S. A. & Siber, G. R., (1985). Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrobial Agents and Chemotherapy 28, 107–12.
7. Ziegler, E. J. (1988). Immunological intervention in endotoxin shock. In Bacterial Endotoxins: Pathophysiological Effects, Clinical Significance, and Pharmacological Control, pp. 319–325. Alan R. Liss, Inc.
8. Ziegler, E., Fisher, C., Sprung, C., Straube, R., Sadoff, J. & the HA1A Sepsis Study Group. (1990). Prevention of death from Gram-negative bacteremia and sepsis by HA–1A, a human monoclonal antibody specific for Lipid A of endotoxin: Results of phase III trial. Clinical Research 38, Abstract 304A.